Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Repotrectinib

5d13c8e6-f80c-5f74-923e-d606030ba965 · FDA Approved · targets ROS_ROS1

Repotrectinib

MeasuredReference

Repotrectinib targets ROS_ROS1, NTRK2, TXK. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

ROS_ROS1NTRK2TXKEPHA2ALK

Top hallmarks

  • tumor promoting inflammation6.8k
  • evading apoptosis5.0k
  • proliferation4.9k

Top pathways disrupted

  • allograft rejection13.0k
  • apical junction12.3k
  • pi3k akt mtor signaling12.1k

Resistance landscape — Repotrectinib

MeasuredReference

10 known oncogenic variants exist on Repotrectinib's top targets — see detail for inhibition impact.

Open in new tab